Pulse Biosciences Inc (PLSE)
NASDAQ: PLSEHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PLSE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.50B
- EPS (TTM)
- -$1.18
- Dividend yield
- None
- 52-week range
- 12.56 – 58.90
- Day range
- 48.13 – 49.93
- Volume / Avg
- 409.47K / 508.04K
- Beta
- —
- Shares outstanding
- 71.32M
- Next earnings
- Nov 4, 2026
52-week range
PLSE stock today
Pulse Biosciences (PLSE) closed at $49.09 on Oct 7, down 1.33% (-$0.66), versus the S&P 500's 0.22% decline. At this level, PLSE sits in the middle of its 52-week range of $12.56 to $58.90: 16.7% below the high, set on Sep 9, 2026 and 290.8% above the low. PLSE is up 257.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 147.1%.
Pulse Biosciences has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful. Pulse Biosciences's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Pulse Biosciences
Company profilePulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Paul Arthur LaViolette M.B.A.
- Headquarters
- Miami, FL
- Employees
- 116
- IPO year
- 2016
- Website
- pulsebiosciences.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$56.50+15.09%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.35
Pulse Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRTCiRhythm Holdings Inc. | 104.99 | -2.06% | $3.46B | vs PLSE |
| NVSTEnvista Holdings Corporation | 23.04 | -0.99% | $3.70B | vs PLSE |
| ICUIICU Medical Inc. | 156.03 | -2.32% | $3.90B | vs PLSE |
| HTFLHeartflow Inc. | 49.36 | -2.62% | $4.29B | vs PLSE |
| ATRCAtriCure Inc. | 53.31 | -0.69% | $2.71B | vs PLSE |
| HAEHaemonetics Corporation | 101.71 | -1.75% | $4.63B | vs PLSE |
| UFPTUFP Technologies Inc. | 292.87 | -3.30% | $2.27B | vs PLSE |
| MMSIMerit Medical Systems Inc. | 85.09 | +0.15% | $5.08B | vs PLSE |
Indexes, lists and sector
Pulse Biosciences stock FAQ
What is Pulse Biosciences's stock price today?
PLSE last traded at $49.09 as of Oct 7, 4:00 PM EDT, down 1.33% on the day. Prices are delayed at least 15 minutes.
When is Pulse Biosciences's next earnings date?
Pulse Biosciences is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.35.
Who is Pulse Biosciences's CEO?
Mr. Paul Arthur LaViolette M.B.A. is the chief executive officer of Pulse Biosciences Inc, which has about 116 employees.
What is the PLSE 52-week high?
The 52-week high for PLSE is $58.90 and the 52-week low is $12.56. The stock is currently 16.7% below its high.